Podcasts about medstar health

Are you up to date with the latest guidelines on deep venous thrombosis (DVT) management? Dr. Steven Abramowitz, vascular surgeon at MedStar Health, joins host Dr. Chris Beck for a deep dive into emerging clinical data in DVT management, where they review the evolving indications for mechanical thrombectomy and the implications of studies like the ATTRACT trial, the CLOUT registry, and the ongoing DEFIANCE trial. --- This podcast is supported by: Inari Medicalhttps://www.inarimedical.com/artix-system --- SYNPOSIS Dr. Abramowitz reviews recent data comparing outcomes of mechanical intervention versus lytic-based therapy, outlining how each approach fits into current practice. He underscores the critical role of IVUS in determining treatment endpoints, while noting the ongoing challenge of an absent standardized definition. The conversation also offers practical insights on procedural techniques and the evolving role of anticoagulation, emphasizing the importance of close collaboration and open communication with referring physicians. --- TIMESTAMPS 00:00 - Introduction00:45 - Overview of DVT Management02:50 - New Guidelines for DVT Treatment07:30 - Technical Endpoints in DVT Treatment13:26 - Clout Registry and Its Findings17:57 - Anticoagulation and DVT23:05 - Defining Acute DVT Management27:00 - Evolving Approaches to Acute DVT28:19 - Patient Experience and Quality of Life31:08 - Referring Providers and Data Impact37:01 - Single Session Treatments and Stenting41:07 - Chronic Venous Disease Management --- RESOURCES (ATTRACT) Weinberg I, Vedantham S, Salter A, et al. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vasc Med. 2019;24(5):442-451. doi:10.1177/1358863X19862043https://pubmed.ncbi.nlm.nih.gov/31354089/ (CLOUT) Shaikh A, Zybulewski A, Paulisin J, et al. Six-Month Outcomes of Mechanical Thrombectomy for Treating Deep Vein Thrombosis: Analysis from the 500-Patient CLOUT Registry. Cardiovasc Intervent Radiol. 2023;46(11):1571-1580. doi:10.1007/s00270-023-03509-8https://pubmed.ncbi.nlm.nih.gov/37580422/ (DEFIANCE) Abramowitz SD, Marko X, D'Souza D, et al. Rationale and design of the DEFIANCE study: A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosis. Am Heart J. 2025;281:92-102. doi:10.1016/j.ahj.2024.10.016https://pubmed.ncbi.nlm.nih.gov/39491572/

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Human Factors in Healthcare AI: Where Patient Safety Meets Real-World Implementation Joining us is Kristen Miller, Co-Director of MedStar Health's Center for Diagnostic Systems Safety and Scientific Director of their National Center for Human Factors in Healthcare. As healthcare organizations invest billions in AI technologies, Kristen's research reveals that human factors engineering - the science of how humans interact with complex systems - determines whether AI becomes a safety enhancer or safety hazard, whether patients embrace or resist these tools, and whether healthcare teams achieve promised efficiencies or face new workflow disruptions. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Would like like to share feedback on this podcast? Or suggest another topic for us to explore? Click here, or email us at DocTalk@medstar.netIn this episode of MedStar Health DocTalk, host Debra Schindler sits down with Dr. Nicole Sakla, a breast radiologist and published researcher in artificial intelligence, to explore how AI is changing the way mammograms are read and how it can help radiologists detect disease earlier, sometimes by years.Learn how AI tools flag subtle patterns invisible to the human eye, act as a double-check system for radiologists, and may reduce unnecessary callbacks and missed cancers—all without replacing the human expertise behind every diagnosis.Dr. Sakla also clears up misconceptions about AI in medicine, explains how it's trained to be accurate across diverse patients, and shares what excites her most about the next generation of AI technology in breast imaging.Listen now for a fascinating, accessible look into how human expertise and machine learning are working together to advance early detection and patient care.For more information about breast imaging and screening at MedStar Health, medstarhealth.org/breasthealth or call the breast center at MedStar Washington Hospital Center: 202-877-2800 .If you would like to comment on this podcast, or recommend a topic for another episode of DocTalk, send an email:  DocTalk@medstar.netFor more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this episode, Bill Sheahan, SVP and Chief Innovation Officer at MedStar Health, shares how the system is leveraging AI, telehealth, and digital innovation partnerships to redesign care models. He highlights the importance of balancing technology with people and process changes to create scalable, patient-centered transformation with clinical, operational, and external partners.This episode is sponsored by eVisit.

On this episode of SurgOnc today, Dr. Rosalinda Alvarado and Dr. George Molina moderate a discussion on how to improve the recruitment of Hispanic/Latino patients into clinical trials. Joining the conversation are Jeanette Gonzalez from the University of Illinois Cancer Center and Alas-Wings, Dr. Narjust Florez from Dana-Farber Cancer Institute and Harvard Medical School, and Dr. Kennedy Timothy from MedStar Health and Georgetown University.

Send us a textIn this episode of our podcast DocTalk, host Debra Schindler sits down with MedStar Health interventional cardiologist Dr. John Wang, director of the Cardiac Catheterization Labs at MedStar Union Memorial Hospital and MedStar Franklin Square Medical Center in Baltimore, to explore how cardiac catheterizations have evolved, and why the transradial approach (through the wrist) is transforming catheterization procedures.Traditionally performed through the femoral artery in the groin, cardiac caths are increasingly going in through the wrist, offering: ·       Faster recovery Fewer complications Greater patient comfort Same-day discharge for many patientsDr. Wang explains:What symptoms may lead to a cardiac cathWhen the procedure is performed in emergencies (like heart attacks) vs. scheduled careWhy national cardiology guidelines recommend the transradial approachWhat patients should ask their doctors before undergoing the procedureIf you or a loved one may need a heart cath, this episode will help you understand your options, and why the accessing the heart through the wrist is a better approach.Learn more about interventional cardiology at MedStarHealth.org/MHVI To comment on this podcast, or suggest a topic for another episode send us an email: DocTalk@medstar.netFor more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Join a conversation with Dr. Carolyn Cumpsty Fowler, JHHS Executive Director for Nurse Well-Being and Dr. Cassie O'Malley, Senior Director of Well-being and Innovation, MedStar Health, on how healthcare leaders can create supportive environments that foster inter-disciplinary team well-being. The … Ep. 17 Well-Being by Design: Building Systems That Support the Whole Team | Johns Hopkins Medicine Office of Well-Being Read More »

Send us a textThe shoulder is the most mobile and most complex joint in the human body, which also makes it vulnerable to injury and arthritis. Each year, nearly 60,000 Americans undergo shoulder replacement surgery, also known as total shoulder arthroplasty (TSA).In this episode of MedStar Health DocTalk, host Debra Schindler sits down with orthopedic surgeon Dr. Ryan Hoffman, a shoulder and elbow specialist at MedStar Health, to explore:·       What shoulder arthroplasty is and when it's needed·       The difference between total vs. reverse shoulder replacements·       How advances like robotic planning, 3D templating, and stemless implants are changing outcomes·       What recovery looks like and how patients regain mobility·       What to ask when choosing a shoulder surgeonIf you've ever wondered about shoulder pain, rotator cuff tears, or when it's time to consider replacement surgery, this conversation breaks it all down.Watch and learn how modern shoulder surgery is helping patients get back to the life they love.For an appointment with Dr. Hoffman call 410-554-2272. If you would like to share feedback on this podcast or suggest a topic for another episode of MedStar Health Doc talk, send an email: debra.schindler@medstar.net. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Symptomatic gallstones that can't be treated with surgery? Interventional radiology can help. In this episode of BackTable, Dr. John Smirniotopoulos, IR at MedStar Health, joins Dr. Michael Barraza to share the latest advancements and techniques in biliary endoscopy. --- SYNPOSIS Dr. Smirniotopoulos reflects on his early work with cholangioscopy at Cornell, highlighting ongoing innovation and evolving tools. The conversation covers the practical aspects of patient selection, procedural steps, and overcoming technical challenges. Dr. Smirniotopoulos shares his personal experiences managing small and large biliary stones, emphasizing the important role of selecting appropriate equipment to navigate procedural challenges. Dr. Smirniotopoulos also highlights the collaborative role of surgeons and gastroenterologists throughout patient management. He also provides insights into the management of biliary strictures and emphasizes the importance of accurate billing and coding. The episode concludes with advice for clinicians seeking to integrate these techniques into their practice. --- TIMESTAMPS 00:00 - Introduction01:09 - Early Experiences with Biliary Endoscopy03:35 - Procedure Techniques and Tools05:36 - Patient Selection and Case Studies11:01 - Advanced Techniques and Equipment14:02 - Patient Management and Follow-Up18:21 - Technical Considerations and Best Practices20:14 - Managing Stones in the Gallbladder35:42 - Collaborating with Surgeons and GI Teams37:59 - Advice for New Practitioners

Send us a textIn this episode of MedStar Health DocTalk, host Debra Schindler speaks with Dr. Othman Abdul-Malak, MD, MSC, a vascular expert, to break down the what carotid artery disease is, and how it can lead to stroke, mini-strokes (TIAs), and sudden vision loss. Learn how to recognize early warning signs—like facial droop, arm weakness, or sudden speech problems—and why acting fast can save brain function. Dr. Abdul-Malak also explains:·       The difference between ischemic and embolic strokes·       What amaurosis fugax means ·       Why age, heart disease, and cholesterol put you at greater risk·       When NOT to take aspirinThis episode is a must-listen for anyone interested in stroke prevention, vascular health, or caring for aging loved ones. Time is brain. Know the signs. Act fast.Subscribe for more expert-led episodes.To make an appointment with Dr. Abdul Malak, call 443-777-1900. If you would like to provide feedback on this podcast or get more information when carotid artery disease or treatment options, send me an to DocTalk@medstar.net For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textIn this episode of MedStar Health DocTalk, host Debra Schindler tackles a topic that many women face but few discuss: urinary incontinence. With an estimated 25 million American women affected, it's time to break the silence. Joined by MedStar Health urogynecologist Dr. Abigail Davenport, they delve into the myths surrounding incontinence, the different types, and the various treatment options available. From urgency incontinence to stress urinary incontinence, Dr. Davenport provides invaluable insights into how lifestyle changes, physical therapy, and advanced therapies can help women regain control over their lives. Tune in to learn why this common issue shouldn't be a source of shame and how empowering conversations can lead to effective solutions.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Is it time for interventional radiology to sever ties with diagnostic radiology and define its own future? Dr. Ally Baheti hosts Dr. Mark Lessne, interventional radiologist at Charlotte Radiology and Dr. Saher Sabri, Chief of Interventional Radiology at MedStar Health, to discuss the evolving relationship between interventional radiology (IR) and diagnostic radiology (DR). --- SYNPOSISThe doctors begin the discussion by asking a critical question: 'What defines an interventional radiologist?' They delve into the different practice patterns of IRs, exploring both the opportunities and challenges in interventional radiology forging its own path, independent of diagnostic radiology. The doctors share their thoughts on the financial implications, sustainability of the specialty, and the importance of establishing a clinical and longitudinal practice. The discussion concludes with the notion that an organic separation is likely inevitable, although the timing remains uncertain. --- TIMESTAMPS 00:00 - Introduction03:45 - Challenges in IR Practice12:23 - Financial Models and Sustainability16:13 - The Role of SIR in Supporting IRs34:29 - Defining IR Standards35:28 - SIR's Role38:29 - Future of IR and DR58:36 - Final Thoughts and Call to Action

In this episode, Sandra Johnson, Vice President & Chief Revenue Officer at MedStar Health, discusses how her team is navigating increasing denials, Medicaid re-enrollment challenges, and regional layoffs—all while leading a major revenue cycle and business transformation. She also shares how building a strong, supportive culture is key to effective leadership in healthcare today.

Send us a textBumps and lumps of the hand can be any number of things...  all are classified as a hand tumor, but do they all require treatment, and which are a cause for concern? Host Debra Schindler explores the various types of hand tumors from the benign to malignant, with hand surgeon and Chief of the Curtis National Hand Center, Dr. James Higgins, and orthopedic oncologist, Dr. Mohammed Karim. Learn about the variety of hand tumors, treatment options, and the importance of early diagnosis. Don't let uncertainty hold you back— peace of mind is everything.   If you have concerns about a hand tumor and would like to see a specialist call 877-34-ORTHO  or 877-346-7846.  If you're from outside the Maryland area, ask for a video consult appointment. If you would like to provide feedback on this podcast, or get more information on hand tumors, send Debra an email:  debra.schindler@medstar.net.   For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this episode, Payton delves into a baffling mystery—multiple hospital patients discovered in the most inexplicable places. NEW MERCH LINK: https://mwmhshop.com Twitch: twitch.tv/throatypie Instagram: https://www.instagram.com/intothedarkpod/ Watch on Youtube: https://www.youtube.com/channel/UCUbh-B5Or9CT8Hutw1wfYqQ Listen on Apple: https://podcasts.apple.com/us/podcast/into-the-dark/id1662304327 Listen on spotify: https://open.spotify.com/show/36SDVKB2MEWpFGVs9kRgQ7 Case Sources: Bhekisisa Centre for Health Journalism - https://bhekisisa.org/article/2019-05-30-00-patient-found-dead-in-hospital-ceiling-durban-mystery/  Mail & Guardian - https://mg.co.za/article/2019-05-30-00-patient-found-dead-in-hospital-ceiling-durban-mystery/  South Africa Human Rights Commission - https://www.sahrc.org.za/index.php/sahrc-media/news/item/970-mysterious-death-of-patient-found-in-hospital-ceiling-must-be-probed  IOL - https://www.iol.co.za/capetimes/news/how-did-patient-end-up-dead-in-hospitals-ceiling-11732163  https://www.iol.co.za/capetimes/news/we-are-losing-hope-family-still-seeks-answers-over-body-found-in-ceiling-24824780  Juta Medical Brief - https://www.medicalbrief.co.za/questions-remain-death-patient-found-hospital-ceiling/  Nehanda Radio - https://nehandaradio.com/2017/10/27/patient-end-dead-hospitals-ceiling/  Sowetan Live - https://www.sowetanlive.co.za/news/2016-03-29-no-body-to-bury-15-years-on/  US National Science Foundation - https://new.nsf.gov/news/teleportation-possible-yes-quantum-world  Esquire Magazine - https://www.esquiremag.ph/culture/lifestyle/gil-perez-teleportation-legend-a2336-20190808?s=e6qi2crg72uran10tp2p446hkh  National Geographic - https://kids.nationalgeographic.com/books/article/could-humans-teleport  How Stuff Works - https://science.howstuffworks.com/science-vs-myth/everyday-myths/teleportation.htm   Medstar Health - https://www.medstarhealth.org/services/abd Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a textIn this episode of MedStar Health DocTalk, host Debra Schindler sits down with gastroenterologist Dr. Jose Parungao to delve into celiac disease, a chronic immune disorder affecting approximately 1 in 100 people in the U.S. As they explore the intricacies of this condition, Dr. Parungao explains how gluten—a protein found in grains like wheat, rye, and barley—triggers an immune response that can lead to a host of health issues, including malabsorption of essential nutrients.Listeners will learn about the varied symptoms of celiac disease, from gastrointestinal distress to neuropsychiatric manifestations, and the challenges of diagnosis that often lead to misinterpretation of symptoms. Dr. Parungao discusses the importance of screening, the diagnostic process involving blood tests and biopsies, and the critical role of a gluten-free diet in managing the disease. With insights into potential genetic links and the importance of family testing, this episode provides a comprehensive overview for anyone curious about celiac disease or seeking to understand its long-term implications.For more information on this podcast, or to schedule an appointment with a gastroenterologist in the Baltimore, Annapolis, Bel Air area, email debra.schindler@medstar.net.---For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textAre you one of the many who experience heartburn or acid reflux? In our latest episode, host Debra Schindler separates fact from fiction about gastroesophageal reflux disease -or GERD- with MedStar Health gastroenterologist Vinshi Khan, MD. Learn why long term complications from GERD make treatment so important. If you have feedback on this podcast, or would like to make an appointment with Dr. Kahn, send us an email, at debra.schindler@medstar.net.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textIn the latest episode of MedStar Health DocTalk, orthopedic surgeon Zan Nasser, MD, who specializes in spine surgery, discusses the facts and fiction of scoliosis. From understanding the basics of curvature of the spine, to treatment options, patients, parents, and healthcare professionals alike, this podcast has something for everyone.Contrary to popular belief, scoliosis isn't solely a teenage affliction nor is it caused by poor posture. In fact, scoliosis can develop in individuals of any age, and its severity varies significantly from person to person. Bracing is often the first line of defense for children with mild to moderate curves, and it plays a crucial role in preventing the curvature from worsening. But when does bracing start, and what happens if treatment isn't pursued. Dr. Naseer has details the issues surrounding bracing for pediatric patients and for adults… with practical advice for parents on how to manage bracing routines.Dr. Naseer delves into the more complex aspects of scoliosis management, including surgery. Listeners will also learn about the importance of early diagnosis and regular monitoring. With expert insights from Dr. Zan Naseer, listeners are empowered to understand scoliosis better and to navigate its challenges with confidence. Tune in to gain a deeper understanding of scoliosis, its management, and how to support those living with it. Don't miss out on this enlightening conversation that could change lives!For more information on Dr. Naseer, go to medstarhealth.org/naseer, or to make an appointment, call 410-248-8054. If you would like to share feedback on this podcast, or suggest a topic for another episode of DocTalk, email Debra Schindler at debra.schindler@medstar.net.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textA groundbreaking innovation is making waves for the approximate six million Americans who suffer with atrial fibrillation (AFib). It's called pulsed field ablation. In our latest podcast episode, host Debra Schindler talks with Dr. Sunjeet Sidhu, a renowned cardiac electrophysiologist at MedStar Health, to explore the intricacies and benefits of this safer, faster, cutting-edge treatment. The number of those suffering with AFib, may even be an underestimate, but statistics show they are steadily increasing due to factors such as an aging population and the obesity epidemic. Traditionally, AFIB treatment involved thermal ablation methods, which, although effective, posed risks of collateral damage to surrounding tissues. Enter pulsed field ablation, a technique that uses ultra-short electrical pulses to target and destroy abnormal heart tissue without harming nearby structures. This method is not only safer but also more efficient, reducing procedure times significantly. Dr. Sidhu explains how pulsed field ablation works by creating a scar tissue barrier, effectively isolating the problematic areas of the heart that trigger AFIB. Unlike thermal ablation, which relies on heating or freezing tissues, pulsed field ablation uses electroporation to disrupt cell membranes, leading to cell death and scar formation. The heart cells are particularly sensitive to this type of injury, allowing for precise targeting without affecting surrounding tissues. The benefits of pulsed field ablation are manifold. Patients experience shorter procedure times, reduced anesthesia exposure, and fewer complications. Dr. Sidhu shares his firsthand experiences, noting a significant improvement in patient outcomes and satisfaction. He recounts a heartwarming story of a young mother who, after undergoing the procedure, was able to regain her quality of life and engage in activities with her children without the debilitating effects of AFIB.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textIn our latest episode of MedStar Health DocTalk, Debra Schindler talks with MedStar Health breast surgeon, Maen Farha, MD, medical director of the Breast Center at MedStar Good Samaritan Hospital in Baltimore, about the most common breast cancer diagnosis: ductal carcinoma in situ (DCIS). Learn more about the contained, early-stage disease, the intricacies of diagnosis, and the personalized treatment options available. Dr. Farha shares valuable experience and a wealth of knowledge with hope for outstanding results, possible with proper care.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textFor more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

This is the eleventh episode of our special podcast series exploring the Sept/Oct themed issue of the American College of Sports Medicine's Health & Fitness Journal on professionalization and advocacy. In this episode, we'll explore the important and complex topic of payment, with Christina Badaracco, the lead author for the article in the themed issue entitled "Compensation for Exercise Professional Services."Christina has an extensive background in clinical research, healthcare policy, and public health program development. She'll provide insights into various reimbursement models, including cash pay, health savings accounts, and insurance reimbursement, and how better understanding these methods and advocating for improvements can increase both accessibility and professional recognition in the exercise field. Christina shares her recent work with Avalere and the Physical Activity Alliance, shedding light on healthcare integration opportunities for interventions delivered by exercise professionals.Discover the hurdles that exercise professionals may face in a changing compensation landscape, from increased paperwork and lower reimbursement rates to the necessity for specialized knowledge and additional staff. We delve into the importance of clear quality measures and evidence-based programs to showcase the impact of fitness on health outcomes and healthcare costs. Additionally, Christina's explore the parallels between physical activity and the food is medicine initiative, and the importance of advocating for better integration, reimbursement, and support for advancing lifestyle medicine. This is an episode packed with strategies and insights critical for all exercise professionals to understand as they travel on their professionalization journey. Show Notes Page: https://wellnessparadoxpod.com/episodeacsm11Our Guest: Christina Badaracco, MPH, RDN, LDNChristina works as a healthcare consultant and nationally recognized thought leader, focusing on advancing the role of nutrition and lifestyle medicine in healthcare. She also regularly writes, teaches, and develops curriculum about nutrition, culinary medicine, and sustainable agriculture—including publishing The Farm Bill: A Citizen's Guide, publishing cookbooks with the Transamerica Institute, and co-developing a culinary medicine course at the Georgetown University School of Medicine and lifestyle medicine shared medical appointment series for MedStar Health in the DC metro area. She is currently guiding a start-up focused on healthy and sustainable food in hospitals and several other innovative food projects. In her most recent full-time role as a healthcare consultant at Avalere, Christina advised various healthcare industry clients (including the Physical Activity Alliance) in care transformation and evidence generation. Christina previously worked for the Environmental Protection Agency, Teaching Kitchen Collaborative, Oakland Unified School District, and other prominent organizations. She serves as president of the DC Metro Academy of Nutrition and Dietetics and a Slow Food DC board member. She earned her MPH from UC Berkeley and her AB in Ecology and Evolutionary Biology, with a minor in Italian, from Princeton University. Follow us on social at the links below: https://www.facebook.com/wellnessparadox https://www.instagram.com/wellnessparadox/ https://www.linkedin.com/company/wellness-paradox-podcast https://twitter.com/WellnessParadox

In this episode of the afikra podcast, we chat with Maha El Akoum, the Manager of Content and Policy at WISH, to try to explore the causes of childhood obesity – especially in the Arab world and particularly in the Gulf – and to understand the complexities of dealing with it. Based in Qatar, Maha discusses the alarming rise in childhood obesity within the Gulf region, but also globally. She explores factors contributing to the epidemic such as lifestyle changes, dietary habits, economic factors, and urban planning. The conversation also covers potential solutions, highlighting successful policies in other nations and outlining the comprehensive approach needed to tackle obesity effectively. Maha emphasizes the societal efforts as well as the policy changes required for meaningful impact.00:00 Understanding the Complexity of Obesity00:18 Introduction to WISH and Its Mission02:38 Childhood Obesity in Qatar and the Region04:07 Factors Contributing to Obesity04:59 Impact of Lifestyle and Economic Development08:07 Global and Regional Contexts of Obesity11:23 Effective Policies and Solutions12:50 Understanding Taxation on Unhealthy Foods13:16 Challenges and Successes of Food Taxation14:33 Public Awareness and Healthy Eating Campaigns15:53 The Societal Impact of Obesity19:23 School-Based Interventions23:22 Trends and Statistics in Childhood Obesity27:20 Global Perspectives and Effective Policies28:56 Comprehensive Policy Interventions39:20 Next Steps and Future Plans41:41 Recommendations and ResourcesMaha El Akoum is the manager of Policy and Content Development at the World Innovation Summit for Health (WISH). Her particular research interests include genomics and precision medicine, global health, health policy, healthcare innovation and health systems development. With a strong interest in patient safety, Maha has led several initiatives on a national level, such as the Academy for Emerging Leaders in Patient Safety in collaboration with MedStar Health, as well spearheading several research projects looking into the role of nurses in creating a culture of safety. Maha also managed what was formerly known as the WISH Young Innovators program (from 2015-2019), where she was involved in the shortlisting of the candidates and overall execution of the program.Connect with Maha

Send us a textLung cancer is the leading cause of cancer deaths in both men and women, resulting in more cancer deaths than breast, prostate, and colorectal cancers combined. It can take years to develop and is difficult to detect in early stages when there is greater potential for a cure. Fortunately, lung cancer survival rates are improving, thanks to advances in screening and treatment options, including breakthrough therapies that we're leading at MedStar Health. In partnership with the Georgetown Lombardi Comprehensive Cancer Center—a National Cancer Institute-designated comprehensive cancer center—we can offer our patients promising clinical trials years before they become the standard of care. Dr. Edward Chan is the Chief of Thoracic Surgery at MedStar Washington Hospital Center. Dr. Chan sees patients at MedStar Washington Hospital Center and MedStar Georgetown University Hospital. Dr. Chan is double-board certified and specializes in general thoracic surgery. He treats patients for lung cancer, esophageal cancer, benign esophageal diseases (such as acid reflux/hiatal hernia and achalasia), and mediastinal tumors. For an interview with Dr. Edward Chan, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net.  Learn more about Dr. Chan. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Send us a textIn this episode of MedStar Health DocTalk, we explore the critical aspects of breast cancer detection and the intricacies of mammography with Dr. Michelle Townsend Day, Chair of the Department of Radiology and Section Chief of Breast Imaging at MedStar Good Samaritan and MedStar Union Memorial Hospitals. Hosted by Debra Schindler, this episode delves into the advancements in breast imaging, the significance of early detection, and the challenges faced in diagnosing breast cancer, particularly in women with dense breast tissue. Dr. Townsend Day provides a comprehensive overview of the different types of mammograms, including 2D and 3D mammography, and explains the role of artificial intelligence in enhancing diagnostic accuracy. She also discusses the importance of understanding breast density and the implications of the recent FDA amendment to the Mammography Quality Standards Act. The conversation covers various imaging modalities, including ultrasound, MRI, and contrast-enhanced mammography, and their applications in breast cancer screening and diagnosis. Listeners will gain valuable insights into the role of radiologists in the diagnostic process, the importance of patient advocacy, and the potential impact of family history on breast cancer risk. Dr. Townsend Day emphasizes the need for regular self-exams and the significance of early detection in improving outcomes for breast cancer patients. For more information on mammograms or to schedule one, visit medstarhealth.org/mammogram.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Valeriy Shubinets, MD, discuss the following articles from the September 2024 issue: “Radial and Ulnar Forearm Free Flaps: A Critical Comparison of Donor-Site Morbidity and Its Impact on Quality of Life” Al-Aroomi, Duan, Al-Worafi, et al. Read the article for FREE: https://bit.ly/RadialUlnarFF Special guest, Dr. Valeriy Shubinets, is a faculty member at The Curtis National Hand Center and MedStar Health. Originally from Ukraine, he obtained his medical degree from Harvard Medical School. He was awarded the Howard Hughes Medical Institute fellowship for a research year before he completed his plastic surgery residency at the University of Pennsylvania, followed by an orthopedic hand fellowship at The Curtis National Hand Center and Union Memorial Hospital. Dr. Shubinets has a diverse clinical practice in hand surgery with a focus on reconstruction and microsurgery including very complex replantations, and he also conducts research to better understand vascular anatomy.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept24Collection

In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Valeriy Shubinets, MD, discuss the following articles from the September 2024 issue: “Wrist-Level Tendon Repairs Utilizing a Novel Tendon Stapler Device: An Efficiency and Biomechanical Study” by Reed, Hendrycks, Graham, et al. Read the article for FREE: https://bit.ly/StaplerDevice Special guest, Dr. Valeriy Shubinets, is a faculty member at The Curtis National Hand Center and MedStar Health. Originally from Ukraine, he obtained his medical degree from Harvard Medical School. He was awarded the Howard Hughes Medical Institute fellowship for a research year before he completed his plastic surgery residency at the University of Pennsylvania, followed by an orthopedic hand fellowship at The Curtis National Hand Center and Union Memorial Hospital. Dr. Shubinets has a diverse clinical practice in hand surgery with a focus on reconstruction and microsurgery including very complex replantations, and he also conducts research to better understand vascular anatomy.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept24Collection

In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Valeriy Shubinets, MD, discuss the following articles from the September 2024 issue:  “Predicting Persistent Opioid Use after Hand Surgery: A Machine Learning Approach” by Baxter, Ho, Byrd, et al. Read the article for FREE: https://bit.ly/PredictingOpioidUse Special guest, Dr. Valeriy Shubinets, is a faculty member at The Curtis National Hand Center and MedStar Health. Originally from Ukraine, he obtained his medical degree from Harvard Medical School. He was awarded the Howard Hughes Medical Institute fellowship for a research year before he completed his plastic surgery residency at the University of Pennsylvania, followed by an orthopedic hand fellowship at The Curtis National Hand Center and Union Memorial Hospital. Dr. Shubinets has a diverse clinical practice in hand surgery with a focus on reconstruction and microsurgery including very complex replantations, and he also conducts research to better understand vascular anatomy.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept24Collection

In episode 89, we welcome back the extraordinary Priya Bathija, founder and CEO of Nyoo Health, to dissect the critical impact of the upcoming election on women's health.Priya is a nationally-recognized healthcare leader, attorney, and policy expert. She is currently Founder and CEO of Nyoo Health, which serves as a guide for healthcare leaders as they improve women's health. Previously, she was at the American Hospital Association where she led policy efforts and strategic initiatives on value, health equity and maternal health. She started her career as a healthcare attorney and served as in-house counsel and a member of the executive leadership teams at ProMedica and MedStar Health. Priya is also a Distinguished Practitioner in Residence at The Ohio State University Moritz College of Law and an adjunct professor at Loyola University Chicago School of Law. Priya is a nationally-recognized healthcare leader, attorney, and policy expert. She is currently Founder and CEO of Nyoo Health, which serves as a guide for healthcare leaders as they improve women's health. Previously, she was at the American Hospital Association where she led policy efforts and strategic initiatives on value, health equity and maternal health. She started her career as a healthcare attorney and served as in-house counsel and a member of the executive leadership teams at ProMedica and MedStar Health. Priya is also a Distinguished Practitioner in Residence at The Ohio State University Moritz College of Law and an adjunct professor at Loyola University Chicago School of Law.Connect with Priya and Nyoo Health:Nyoo Health LinkedInPriya's LinkedInNyoo Health WebsiteNyoo Health InstagramResources:Kaiser Family FoundationAmerican College of Physicians Connect with USS: United SHE Stands InstagramThis episode was edited by Kevin Tanner. Learn more about him and his services here:Website: https://www.kevwyxin.com/Instagram: @kevwyxinIf you purchase from any links to resources or products, the show may make a small commission.

Foot pain is a common issue that many of us face at some point in our lives. While plantar fasciitis is often the culprit, there's another- probably under-reported condition that deserves attention: plantar fibromatosis, also known as Ledderhose disease. In our latest podcast episode, Debra Schindler takes a dive deep into this lesser-known condition with MedStar Health podiatric foot and ankle surgeon, Dr. Paul Carroll.Plantar fibromatosis affects approximately 200,000 people in the United States and is characterized by the growth of fibromas—benign nodules—on the plantar fascia, the thick band of tissue that runs along the bottom of your foot. Unlike plantar fasciitis, which typically causes heel pain that improves throughout the day, plantar fibromatosis presents as a constant pain in the middle part of the foot. Patients often describe feeling a pea-sized bump on the bottom of their foot, which can become painful as it grows.Dr. Carroll explains that while this condition is generally benign, it can be quite painful and debilitating if left untreated. The demographic most affected includes males, diabetics, individuals with chronic alcohol use, and those who have experienced trauma to the foot. Interestingly, there is also a significant correlation between plantar fibromatosis and Dupuytren's contracture, a condition affecting the hands.So, what should you do if you suspect you have plantar fibromatosis? Dr. Carroll advises seeking medical attention as soon as you notice any unusual bumps or persistent pain in your foot. Early diagnosis can help manage the condition more effectively and may prevent it from worsening. While there are several treatment options available, including conservative measures like custom orthotics and steroid injections, surgical options are often considered when other treatments fail. However, surgery comes with its own set of challenges, including a high recurrence rate of the fibromas.One of the more promising treatments discussed in the episode is the use of hyaluronidase injections, which help to shrink and soften the fibromas, making them less symptomatic. Dr. Carroll shares his experiences and success stories with this treatment, providing hope for those suffering from this condition.If you're experiencing unexplained foot pain or have noticed a bump on the bottom of your foot, don't ignore it. Tune in to our latest episode with Dr. Paul Carroll to learn more about plantar fibromatosis, its symptoms, and the various treatment options available. Your foot health is essential, and early intervention can make all the difference.Listen to the full episode now and take the first step towards better foot health!For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Stephen Evans, Chief Medical Officer at MedStar Health, discusses his company's  program designed to support women through all stages of pregnancy. He also explores initiatives aimed at simplifying access to care, making healthcare more accessible and efficient for all patients.

In our latest podcast episode, we delve into the fascinating world of brain waves and neurological diagnostics with Dr. Syed Shabbir, Director of Epilepsy and Medical Director of the EEG Lab at Medstar Franklin Square Medical Center. Hosted by Debra Schindler, this episode sheds light on the complexities of the human brain and the critical role of electroencephalograms (EEGs) in diagnosing and treating neurological disorders. The human brain is an intricate organ, constantly firing neurons and generating electrical activity known as brain waves. These brain waves can be measured using EEGs, a non-invasive method that records macroscopic electroactivity in the brain. Dr. Shabbir explains that EEGs are essential for diagnosing conditions like epilepsy, where abnormal electrical activity can lead to seizures.Dr. Shabbir shares his expertise on how EEGs are conducted, the importance of sleep in detecting abnormalities, and the difference between epileptic and non-epileptic seizures. This episode is a must-listen for anyone interested in neurology and brain health. To schedule an appointment with Dr. Shabbir or another member of MedStar Franklin Square's neurology team, call 443-777-7320.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

 | Join us for an insightful episode with Dr. Kieran Dunleavy, an internationally recognized expert in lymphoma and blood cancers. Learn about the innovative treatments and clinical trials happening at Medstar Georgetown University Hospital that are transforming patient care. Discover how accurate diagnosis and cutting-edge therapies like CAR T cells and bispecific antibodies are improving outcomes and reducing toxicity. Don't miss this opportunity to stay informed about the future of cancer treatment. Listen now! For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Give us about fifteen minutes daily, and we will give you all the local news, sports, weather, and events you can handle.   SPONSORS: Many thanks to our sponsors… Annapolis Subaru, the SPCA of Anne Arundel County,  Solar Energy Services, and Hospice of the Chesapeake. Today... Police release the BWC footage of a police-involved shooting. A Crofton man is dead after a serious crash. MedStar Health is being sued for its second data breach. And, the MDTA has some suggested drive times if you are looking to avoid the Memorial Day Weekend bridge traffic. And, of course, we have info on the Local Business Spotlight coming up this Saturday at noon! Link to daily news recap newsletter: https://forms.aweber.com/form/87/493412887.htm Back with her weekly Annapolis After Dark is BeeprBuzz. She'll keep you up to speed on all of the fantastic live music we have in the area! And as usual, George from DCMDVA Weather is here with your local weather forecast! Please download their app to keep on top of the local weather scene! DAILY NEWSLETTER LINK: https://forms.aweber.com/form/87/493412887.htm The Eye On Annapolis Daily News Brief is produced every Monday through Friday at 6:00 am and available wherever you get your podcasts and also on our social media platforms--All Annapolis and Eye On Annapolis (FB) and @eyeonannapolis (TW) NOTE: For hearing-impaired subscribers, a full transcript is available on Eye On Annapolis.

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Secretary Blinken and Senator Warner weigh in on cybersecurity at RSA Conference. Ransomware profits are falling. Proton Mail is under scrutiny for information sharing. A senior British lawmaker blames China for a UK cyberattack. Medstar Health notifies patients of a potential data breach. A study finds cybersecurity education programs across the U.S vary wildly. Brandon Karpf, N2K Man on the Street, stops by to share his thoughts on the 2024 RSA Conference. An Australian pension fund gets lost in the clouds. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guests Brandon Karpf, N2K Man on the Street, stops by to share his thoughts on the 2024 RSA Conference.  Selected Reading Blinken unveils State Dept. strategy for ‘vibrant, open and secure technological future' (The Record) Warner: Lawmakers 'in process' of finding Section 702 fix (The Record) Ransomware operations are becoming less profitable (Help Net Security) Proton Mail Discloses User Data Leading to Arrest in Spain (Restore Privacy) UK says defence ministry targeted in cyberattack (Digital Journal) Novel attack against virtually all VPN apps neuters their entire purpose (Ars Technica) MedStar Health data breach affects 183,079 patients (WUSA9) Researchers say cybersecurity education varies widely in US (Tech Xplore) System outage affecting UniSuper services (UniSuper)  UniSuper private cloud, secondary systems taken out by "rare" Google Cloud "issues" (iTnews) Superannuation: What It Is, How It Works, Types of Plans (Investopedia) Share your feedback. We want to ensure that you are getting the most out of the podcast. Please take a few minutes to share your thoughts with us by completing our brief listener survey as we continually work to improve the show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at cyberwire@n2k.com to request more info. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc.

In older adult care, every moment is precious, and every detail counts. In this episode, Kurt Martin brings a wealth of knowledge and a heartfelt commitment to improving care systems for older adults. By fostering an integrative care model that transcends traditional healthcare settings and emphasizing the value of interdisciplinary teams, Kurt highlights how one can optimize precious minutes of patient-care-provider interaction, resulting in noticeable decreases in hospital and emergency room utilization among his patients. Settle in and gain insights into the profound impact of tailored, comprehensive care strategies in enhancing the lives of older adults in our communities. Resources: Connect and follow Kurt Martin on LinkedIn. Follow MedStar Health on LinkedIn. Discover the MedStar Health Website!  About Memora Health: Memora Health, the leading intelligent care enablement platform, helps clinicians focus on top-of-license practice while proactively engaging patients along complex care journeys. Memora partners with leading health systems, health plans, and digital health companies to transform the care delivery process for care teams and patients. The company's platform digitizes and automates high-touch clinical workflows, supercharging care teams by intelligently triaging patient-reported concerns and data to appropriate care team members and providing patients with proactive, two-way communication and support.

Join us in this episode as we sit down with Scott T. MacLean, Senior Vice President and Chief Information Officer at MedStar Health. Discover key insights into MedStar Health, including recent investments and Scott's focus on engineering talent in healthcare. Tune in for valuable discussions on recruiting, retaining, and growing engineering talent in the healthcare sector, offering a fresh perspective amid clinician shortages.

On today's episode of The Executive Appeal join Alex Tremble (CEO of GPS Leadership Solutions & Keynote speaker) and Nicole Killette (Human Resources Director at MedStar Health) as they reveal powerful insights on eliminating distractions to discover authentic happiness. Learn actionable strategies to gain clarity, understand personal desires, and achieve fulfillment in both professional and personal spheres. Tune in to this enlightening episode and embark on a journey toward genuine happiness and self-awareness.BioNicole joined MedStar Medical Group, LLC in 2016 as an HR Business Partner providing support primarily to specialty service lines and in 2019, she was promoted to HR Manager and began providing HR guidance to a team of HR professionals. In 2021, Nicole was again promoted to Director, Human Resources and currently oversees HR support for almost 4,000 associates, leaders and physicians. Throughout her career, Nicole has conducted many leader trainings in healthcare and human resources, served as a presenter in several Leadership Development Forums, worked as one of the primary trainers for many of MedStar's HR initiatives and served as a strategic partner in assisting with the development of career ladders for many entry-level healthcare positions.When asked why she has always worked in healthcare and never tapped into other industries, Nicole stated that she believes there's nothing more important than providing care for those who care for patients! Prior to her role at MedStar Nicole served in leadership positions at HCR ManorCare and The League for People with Disabilities.

Did you know that Colorectal cancer is the second-leading cause of cancer deaths in the United States in men and women combined? March is Colorectal Cancer Awareness Month. On this episode of our DocTalk podcast, we're discussing colon cancer. Dr. Priyanka Kanth, the Director of the Gastrointestinal Cancer Prevention Program at MedStar Georgetown University Hospital talks about every aspect of colon cancer from symptoms, stages, causes, and treatment.Having accurate facts about colon and rectal cancer is very important. Whether you're reporting on a story, doing a homework assignment, or raising awareness with family, it is important to know the colon cancer signs, symptoms and risk factors.Dr. Kanth sees patients and families with high risk for gastrointestinal cancers at MedStar Georgetown University Hospital. Her area of special interest and expertise is gastrointestinal cancer, especially hereditary colon cancer and colon cancer prevention.For an interview with Dr. Priyanka Kanth, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net.Learn more about Dr. Kanth.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

The course of the Digitalization of Health doesn't always run smooth. But for every set of pain points a provider might experience, there are companies developing technological solutions – platforms and tools – that not only guide us through digital transformation but identify crucial patient and population data along the way.In this episode, we talk with two health tech leaders, interviewed during NCQA's 2023 Health Innovation Summit in Orlando, Florida, about their strategies and successes in using digital tools that can ultimately reveal and resolve gaps in health care delivery.Sebastian Seiguer, is co-founder and CEO of Scene Health. Scene Health is a company focused on medication “engagement”, a comprehensive approach that means more than just getting patients to take their medicine. They provide personalized medication support by combining video technology, clinical coaching, and validated interventions to improve medication adherence rates. Within the tapestry of their mission is the clear goal of reaching and engaging with diverse, vulnerable, and hard-to-reach populations.Upendra Patel, CEO of AaNeel Infotech, is finding ways to support clinicians through EHR, or Electronic Health Record, interoperability. AaNeel Infotech worked with Medstar Health to transform an isolated risk calculator into a FHIR-based app. Upendra's company helped them use the SMART on FHIR methodology. That's FHIR as in “Fast Health Interoperability Resources” and SMART as in “Substitutable Medical Applications and Reusable Technologies”. Using the SMART on FHIR approach, AaNeel Infotech helped create an app called “Mobilizing a Million Hearts”, which integrates the Million Hearts Longitudinal Atherosclerotic Cardiovascular Disease risk calculator into the MedStar Health EHR system and allows Medstar providers to get an even more comprehensive view of their patients at risk for cardiovascular disease.

This episode is a bonus episode, brought to you in partnership with Nyoo ("New") Health. Nyoo hosts the "What's Nyoo!" series, with monthly events that bring together women and experts to have engaging, honest, and educational conversations about women's health, and this one is all about Pelvic Health. This event blew us away, and we knew we had to share it. Special thanks to Priya Bathija - CEO of Nyoo - for allowing us to share this recording. We hope you enjoy it just as much as we did!Remember to like, rate and subscribe and enjoy the episode!Guest biosPriya Bathija is a nationally-recognized healthcare leader, attorney, and policy expert. She is currently Founder and CEO of Nyoo Health, an organization dedicated to improving health and healthcare for women. Previously, she was at the American Hospital Association where she led policy efforts and strategic initiatives on value, health equity and maternal health. She started her career as a healthcare attorney and served as in-house counsel and a member of the leadership teams at ProMedica and MedStar Health. Priya is also a Distinguished Practitioner in Residence at The Ohio State University Moritz College of Law and an adjunct professor at Loyola University Chicago School of Law. In addition, she serves as a public board member for the American Board of Medical Specialties, the largest physician-led specialty certification organization in the U.S.Carine Carmy is CEO and Co-Founder at Origin, the leading provider of pelvic floor and women's physical therapy. She has focused her career on increasing access to products and services that improve lives, from healthcare to 3D printing. Carine's passion for women's health started in her twenties, when she struggled with painful sex for nearly a decade.  Following years of misdiagnoses, ineffective treatment options, and hearing “that's just the way it is,” Carine discovered the power of pelvic floor physical therapy to treat, not only pelvic pain, but dozens of conditions and symptoms that impact some 40 million U.S. women and individuals with vaginal anatomy, every year. Already a go-to-market leader in healthcare and technology — with leadership roles at Amino, Shapeways, MarketspaceNext and Monitor Group — she felt compelled to help make pelvic health the norm for women across the country. Outside of Origin, Carine is an avid writer and has been published in MIT Technology Review, Forbes, Ad Age, and PSFK, and serves as an advisor to startups and nonprofits in support of diversity and economic equality.Dr. Somi Javaid is a board-certified OB/GYN, leading women's sexual health thought leader, and menopause advocate. She is the Founder and Chief Medical Officer of HerMD, a team on a mission to make women's healthcare exceptional by educating, advocating for, and empowering patients to take control of their health concerns. Dr. Javaid has been featured in Forbes, Vogue, Well+Good, InStyle, Parents, Refinery29, Mashable, Adweek, and Popsugar. In August 2020 Dr. Javaid spoke about Gender Bias and the Female Sexual Health Revolution on the TEDx mainstage, and in January 2021 she was featured in Women on Topp for her work as a trailblazer and pioneer in women's sexual health.Dr. Rachel Rubin is a board-certified urologist and sexual medicine specialist. She is an assistant clinical professor of Urology at Georgetown University and owns her private practice in the Washington DC region. She is one of only a handful of physicians fellowship trained in male and female sexual medicine. Dr. Rubin is a clinician, researcher, and vocal educator in the field of sexual medicine. In addition to being education chair for the International Society for the Study of Women's Sexual Health (ISSWSH), she also serves as an Associate Editor for the Journal Sexual Medicine Reviews. Her work has been featured in the NYT and PBS.Emma Schmidt, PhD, is a doctor in Clinical Sexology, a Professional Clinical Counselor, Supervisor, and Certified Sex Therapist, Supervisor through the American Association for Sex Educators Counselors and Therapists (AASECT) as well as the American Board for Christian Sex Therapists (ABCST). She is the owner of Emma Schmidt and Associates in Cincinnati, Indian and Kentucky, a therapy group practice which focuses on sex and relationship therapy. Dr. Schmidt received her Bachelor of Arts in Biblical Studies and Psychology as well as a Master of Arts in Counseling from Cincinnati Christian University. She received her Doctorate from Modern Sex Therapy Institutes. Her research and publications have focused on female sexual pain.Organization bioNyoo Health provides strategic and advisory support to startups, investors, providers, and others as they grow and scale new ways of delivering health and healthcare to women. Beyond that, Nyoo Health is building a movement that will redefine women's health and investing in women as they advocate for themselves in the healthcare system.FemTech Focus Podcast bioThe FemTech Focus Podcast is brought to you by FemHealth Insights, the leader in Women's Health market research and consulting. In this show, Dr. Brittany Barreto hosts meaningfully provocative conversations that bring FemTech experts - including doctors, scientists, inventors, and founders - on air to talk about the innovative technology, services, and products (collectively known as FemTech) that are improving women's health and wellness. Though many leaders in FemTech are women, this podcast is not specifically about female founders, nor is it geared toward a specifically female audience. The podcast gives our host, Dr. Brittany Barreto, and guests an engaging, friendly environment to learn about the past, present, and future of women's health and wellness.FemHealth Insights bioLed by a team of analysts and advisors who specialize in female health, FemHealth Insights is a female health-specific market research and analysis firm, offering businesses in diverse industries unparalleled access to the comprehensive data and insights needed to illuminate areas of untapped potential in the nuanced women's health market.Episode ContributorsPriya BathijaLinkedIn: @Priya Bathija Carine CarmyLinkedIn: @Carine Carmy & @OriginInstagram: @carinerachelle & @theoriginway Dr. Somi JavaidLinkedIn: Somi Javaid, MD & HerMDInstagram: @somijavaidmd & @hermdhealth Dr. Rachel RubinLinkedIn: @Rachel RubinInstagram: @drrachelrubin Dr. Emma SchmidtLinkedIn: @Dr. Emma SchmidtInstagram: @heyemmatherapy Nyoo HealthWebsite: https://www.nyoohealth.com/LinkedIn: @Nyoo HealthInstagram: @nyoohealth  Dr. Brittany BarretoLinkedIn:  @Brittany Barreto, Ph.D.Twitter: @DrBrittBInstagram: @drbrittanybarreto FemTech Focus PodcastWebsite: https://femtechfocus.org/LinkedIn: https://www.linkedin.com/company/femtechfocusTwitter: @FemTech_FocusInstagram: @femtechfocus FemHealth InsightsWebsite: https://www.femhealthinsights.com/LinkedIn: @FemHealth Insights

We're taking a break from releasing new episodes for a few weeks over the holidays. This week, we dug into our vault and are re-releasing our episode on the Issues Women Face in Healthcare with Priya Bathija.  Don't worry! We'll be back in action with new episodes in the new year.Original Air Date: June 13th, 2023We sit down for a conversation with Priya Bathija to chat about the many challenges women face in our healthcare system, and how Priya is part of the movement to finding solutions.  Spoiler alert, problems with women's health go far beyond the issues with maternal healthcare! Priya Bathija is the founder and CEO of Nyoo Health, an organization dedicated to improving access and redefining health and healthcare for women. She is also an adjunct professor at Loyola University Chicago School of Law where she teaches healthcare payment and policy.Previously, she was at the American Hospital Association where she led policy efforts and strategic initiatives on value, health equity and maternal health. She started her career as a healthcare attorney and served as in-house counsel and a member of the leadership teams at ProMedica and MedStar Health.She currently serves on a number of non-profit boards, including the American Board of Medical Specialties, The Policy Center for Maternal Mental Health, and the South Asian Bar Association of North America.Contact Priya BathijaEmail: pbathija@nyoohealth.comNyoo Health Website: Nyoo HealthPriya on LinkedIn: Priya Bathija | LinkedInNyoo Health Instagram: @nyoohealthLet's connect: United SHE Stands InstagramResourcesArika Trim FoundationIf you purchase from any links to resources or products, the show may make a small commission.

On this episode, Mark Glicini sits down with Jay Dyer, the Head Strength and Conditioning Coach for Team USA's Men's and Women's National Teams. For over two decades, Jay has worked with the John's Hopkin's Men's Lacrosse Team and has been the Director of Sports Performance at MedStar Health. Along with being a certified strength and conditioning specialist, he is a devoted husband and father of two kids. Owner and operator of JDyer Strength and Conditioning, Jay brings a degree in Exercise Science and over 20 years of experience with United States' best lacrosse players in the world to help athletes become immensely agile, durable and powerful. Listeners will hear about the importance of "constantly proving yourself," "being able to attribute strength to the field," and "having an appreciation for your craft."

This episode features Ethan Booker, MD, Chief Medical Officer of Telehealth and Medical Director at MedStar Telehealth Innovation Center, MedStar Health. Here, he discusses his background, the evolution of telehealth since March of 2020, where he sees the best opportunities for growth in the future, and more.

Angela D. Thomas, DrPH, MPH, MBA, Vice President, Healthcare Delivery Research, MedStar Health Research Institute, joins Eric to discuss D.C. Safe Babies Safe Moms, a community-driven collaborative launched in 2020 to improve the health and well-being of mothers and infants in Washington, D.C., and reduce racial disparities in maternal and infant health outcomes – one of the most urgent challenges facing the District of Columbia.   Combining the expertise of MedStar Health, evidence-based healthcare, and proven community-centric support services, Safe Babies Safe Moms offers services to support birthing individuals before, during, and after pregnancy and until their child reaches age three.    Angela shares success stories from families supported by the initiative and discusses the program's impact. For health systems interested in implementing a similar program, she outlines MedStar Health's steps in building and sustaining the initiative.     She also speaks about the role technology plays in the initiative. Safe Babies and Safe Moms recently launched a Clinton Global Initiative (CGI) Commitment to Action project to use artificial intelligence and machine learning to help reduce disparities in maternal and infant health.   About Safe Babies Safe Moms Made possible by the A. James & Alice B. Clark Foundation, D.C. Safe Babies Safe Moms is a partnership between MedStar Health, Community of Hope, and Mamatoto Village to address critical maternal and infant care disparities in Washington, D.C., which has among the highest rates of maternal and infant mortality in the nation. In FY22, 15,346 mothers and babies received care through the program.   Services offered include on-site mental health support during prenatal and postpartum visits, assessments for high-risk or complicated pregnancies, social support services for mothers and families who may be experiencing food or housing insecurity, pro-bono legal services, and other counseling on securing public benefits, transportation to and from appointments, infant care supplies, culturally-aware breastfeeding support, and more.   About Angela  Angela is responsible for leading a team of experts to apply rigorous scientific methods to enable next-generation healthcare delivery through quality, safety, innovation, health economics, payment reform, outcomes, health services research, data science, and health equity. She also ensures that these research activities leverage the collective leadership and unique strengths of MedStar Health and Georgetown University. Her research interests focus on health equity and patient safety. As the Executive Leader of Safe Babies Safe Moms, Angela is responsible for ensuring the development, implementation, and evaluation of an evidence-based program that will reduce disparities in maternal and infant mortality in Washington, DC. In addition, she contributes her research expertise in disparities, health equity, and patient safety to the initiative to uncover the contributing factors leading to disparities in maternal and infant harm.   Connect with us on social media: Facebook: facebook.com/brightspotshc Instagram: instagram.com/brightspotshc LinkedIn: linkedin.com/company/shared-purpose-connect Twitter: twitter.com/BrightSpotsinHC TikTok: tiktok.com/@brightspotshc

During a recent two-month period, Maryland and Pennsylvania-based trial lawyers Briggs Bedigian and Jon Stefanuca obtained verdicts of $34 million and $187 million in back-to-back trials in complex birth injury cases.  Join Ben and Rahul for their discussion with Briggs and Jon about their path to handling these challenging, highly leveraged, and risky cases, and the strategies they have developed for sustained and repeated success.  Whether you handle birth injury cases or not, this episode contains important lessons that will benefit anyone who tries cases for a living. About Briggs BedigianH. Briggs Bedigian (“Briggs”) is a trial lawyer dedicated to representing victims of medical malpractice and catastrophic personal injuries nationwide. Briggs and his partner, Charles Gilman, co-founded Gilman & Bedigian, LLC with one guiding principle – to provide the absolute best legal representation to those most in need.   Briggs' particular set of trial skills sets him apart from his peers when he steps into the courtroom. His familiarity with the trial process and his humility and comfort trying cases in front of juries has proven both persuasive and productive. Briggs has tried more than 70 cases to verdict, including winning the largest medical malpractice verdict in Pennsylvania history, $182 million on behalf of a catastrophically injured child. His record of success also includes winning the second largest medical malpractice verdict in Maryland history of $55 million.   While Briggs prepares every case for trial, he routinely achieves multimillion-dollar pre-trial settlements, many in excess of eight-figures. Experience has proven that the hard work of trial preparation and his assertive strategy has been crucial to his success.   Briggs has earned a reputation in the legal community as the “go-to attorney” for catastrophic medical malpractice and personal injury cases. When judges, defense lawyers, doctors, and prominent lawyers refer Briggs their serious personal injury cases, you know he is providing top notch legal representation – and getting top results.   Bar Admissions:  Maryland  Pennsylvania  District of Columbia  United States District Court of Maryland  United States District Court for the District of Columbia   Special Admissions by way of Pro Hac Vice:  Virginia  Texas  Alabama  New Jersey  Georgia  Delaware  North Carolina  Ohio  Nevada   Education:  University of Baltimore School of Law, J.D.  Honors: Top 10% of class  Ithaca College, New York, B.A.  All American football player  Captain of College football team – elected by teammates.   Professional Associations and Memberships:  The Inner Circle of Advocates (Inducted 2015)  Maryland Association for Justice (Elected to Board of Governors)  Philadelphia Trial Lawyers Association (Elected to Board of Governors)  Pennsylvania Association for Justice  The American Association for Justice  Maryland State Bar Association  Baltimore City Bar Association   Honors and Awards:  2013 Trial Lawyer of the Year – Maryland Trial Lawyers Association  2016 Named as one of Maryland's Top 100 Lawyers – Super Lawyers Magazine  Named as “Super Lawyer” in the field of medical malpractice by Maryland Super Lawyers Magazine  Named as a ‘Rising Star” in the field of medical malpractice and personal injury by Baltimore Magazine's Maryland Super Lawyers  The Heuisler Honor Society  Named in The National Trial Lawyers Top 40 under 40    About Jon Stefanuca   As a trial attorney at Gilman & Bedigian, LLC, Jon handles a variety of medical malpractice and personal injury cases. Jon has extensive experience with cases involving catastrophic injuries, including, but not limited to:  Cerebral Palsy  Pediatric brain injury  Hypoxic Ischemic Encephalopathy  Developmental delays  Brain bleeds/ strokes  Neurologic injuries  Musculoskeletal injuries  Infections/ sepsis/ meningitis  Surgical injuries  Anesthesia injuries  Paraplegia/ quadriplegia  Traumatic brain injuries (TBI)  Spinal cord injuries   Jon dedicates most of his time to helping children injured by medical negligence, including children diagnosed with cerebral palsy, hypoxic ischemic encephalopathy, and developmental delays.   Beyond medical negligence, Jon has extensive experience with toxic exposure cases, including carbon monoxide poisoning and lead paint poisoning.   He has handled hundreds of birth injury cases around Maryland and across the country. Some of his recent jury verdicts speak for themselves:  $182,000,000, Birth Injury: Hagans v. Hospital of the University of Pennsylvania  $34,000,000, Birth Injury: Anderson v. University of Maryland St. Joseph Medical Center  $20,000,000, Intellectual property dispute: Adcor Industries, Inc. v. Beretta USA Corp.  $13,300.000, Birth Injury: Lewis v. Upper Chesapeake Medical Center   In addition to medical malpractice litigation, Jon has extensive experience with toxic exposure cases, including carbon monoxide and lead paint cases. His experience includes class actions, mass actions, business disputes, contract disputes, intellectual property disputes, and non-disclosure agreement .litigation.  Verdicts and settlements in excess of $350,000,000.00.  America's Top 100 Medical Malpractice Litigators by America's Top 100.  “Nation's Top One Percent” of attorneys by National Association of Distinguished Counsel.  Power List for medical malpractice and personal injury by The Daily Record.  Board Member, Maryland Association for Justice, the largest trial lawyers' association in the State of Maryland.  Member, American Association for Justice.  Maryland Super Lawyer in the field of medical malpractice by Super Lawyers Magazine since 2020.  Rising Star in medical malpractice by Maryland Super Lawyers Magazine since 2011.  Maryland Top 10 under 40 for medical malpractice in 2015.   Prior to joining Gilman & Bedigian, LLC, Jon was a trial attorney with Murphy Falcon & Murphy, a nationally recognized group of elite trial lawyers. Jon represented the injured in a variety of cases involving medical malpractice, catastrophic personal injuries, product defects, brain injuries, lead poisoning, and carbon monoxide poisoning, among other cases. He was a member of the litigation team in the class action filed against St. Joseph Medical Center and Dr. Mark Midei, which culminated in a $37,000,000.00 settlement. Jon was also a member of the litigation team in the class action filed against Kennedy Krieger Institute, involving allegations of unethical and unlawful experimentation on children. Jon also developed a reputation for representing professional athletes and their families in personal injury cases.   Unlike most other attorneys, Jon has experience representing both plaintiffs and defendants. Jon was a litigation associate with Nash & Associates, LLC, where he represented MedStar Health, a $4 billion health care system in the Baltimore area with a network of nine hospitals and twenty other health-related businesses across Maryland and the Washington, D.C. region. As a result of this experience, Jon has a unique understanding of medical malpractice defense mentality and strategy.   Jon served a judicial clerkship for the Honorable W. Michel Pierson, Circuit Court Judge of the Circuit Court for Baltimore City, prior to entering private practice.   EDUCATION  Jon graduated with honors from the University of Maryland School of Law. He served as the Articles Editor on the Board of the Maryland Law Journal of Race, Religion, Gender, and Class. He was also admitted as a member of the school's Moot Court Board. As a student attorney, he represented a number of community organizations in the Economic Housing and Community Development Law Clinic for which he received a Special Achievement Award.   LANGUAGES  In addition to English, Jon speaks Russian, French and Romanian.   PUBLICATIONS  Jon Simon Stefanuca, The Fall of the Federal Election Campaign Act of 1971: A Public Choice Explanation, 19 U. Fla. J.L. & Pub. Pol'y 237 (2008).  Jon Simon Stefanuca, Crawford v. Washington: The Admissibility of Statements to Physicians and the Use of Closed-Circuit Television in Cases of Child Sexual Abuse, 5 U. Md. L. J. Race, Rel. Gender & Class 411 (2005).  Jon Simon Stefanuca, The PRI and Its Demise as Mexico's Single Ruling Party, 38 Towson U. J. Int'l Aff. 32 (2002).  Jon Simon Stefanuca, The ICC and the United States: Arguments in Favor of Ratification of the Rome Treaty, 37 Towson U. J. of Int'l Aff. (2001). 

We sit down with Nephthalee Edmond Tefera, Healthcare System Director for MedStar Health, to discuss the importance of gender inclusivity in healthcare, leading people through times of uncertainty, and DEI education and awareness in the sciences.

September 8, 2023: In this enlightening episode, Bill talks to Scott MacLean, CIO for MedStar Health about the intricacies, challenges, and opportunities presented by AI technology. Scott reflects on the balance between personal and professional life, sharing his own wellness journey as an empty nester and marathon runner. How does Scott's focus on personal health translate into effective leadership in healthcare? What challenges arise when adopting generative AI, especially on the clinical side where issues like PHI and accuracy must be considered? The conversation also delves into Scott's role on the policy steering committee of Chime, an organization evolving with the role of the CIO. How is Chime helping to shape policy in D.C., particularly around issues like unique patient identifiers and rural broadband? Lastly, the discussion pivots to vendor relationships, offering valuable insights for any vendor aiming to work with CIOs.Key Points:AI in HealthcareWork-life BalancePolicy AdvocacyVendor RelationshipsRural Healthcare ChallengesSubscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer